HUGE

FSD Pharma Inc. [HUGE] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

HUGE Stock Summary

In the News

HUGE Financial details

Company Rating
-
Market Cap
24.14M
Income
-22.13M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
17
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-1.5
Forward P/E
-
PEG
2.37
P/S
-
P/B
2.67
P/C
-
P/FCF
-2.44
Quick Ratio
2.12
Current Ratio
2.2
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.56
EPS next Y
-
EPS next Q
-
EPS this Y
-21.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-39.25%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
49.13%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-139%
ROE
-129%
ROC
-1.94%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.556-1.969
52W High
-
52W Low
-
RSI
-
Rel Volume
162.33
Avg Volume
135.62K
Volume
22.02M
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-97.81%
-
-
-
-
Beta
0.914
-
-
Volatility
1.69%, 1.69%
Prev Close
-97.65%
Price
0.0899
Change
-97.76%

Something similar

Top by Market Cap
LLY
MIX.JO
VTSAX
BRYN.DE
NVDA
Same Sector
CNST
0503.HK
RETA
LNSR
AFX.DE
Check Those
MTC
HIBL
009290.KS
603822.SS
ZSRL.DE
Similar Market Cap
MR-UN.TO
ESGY
CSA
JT
TALK.ST

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 135.62K
  • Market Capitalization 24.14M
  • Employee 17
  • CEO Mr. Zeeshan Saeed
  • Headquarters Toronto,ON,CA
  • IPO Date 2018-06-08
  • Website https://www.fsdpharma.com

FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.